Inicio4559 • TYO
add
Zeria Pharmaceutical Co Ltd
Cierre anterior
2244,00 ¥
Intervalo diario
2247,00 ¥ - 2274,00 ¥
Intervalo anual
1921,00 ¥ - 2411,00 ¥
Cap. bursátil
119,94 mil M JPY
Volumen medio
63,62 mil
Relación precio-beneficio
11,86
Rentabilidad por dividendo
1,99 %
Bolsa de valores principal
TYO
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
(JPY) | sept 2024info | Cambio interanual |
---|---|---|
Ingresos | 20,97 mil M | 14,11 % |
Gastos operativos | 12,52 mil M | 14,20 % |
Ingresos netos | 1849,00 M | -25,47 % |
Margen de beneficio neto | 8,82 | -34,67 % |
Beneficios por acción | — | — |
EBITDA | 4391,00 M | 8,29 % |
Tipo impositivo efectivo | 17,59 % | — |
Balance general
Activos totales
Responsabilidades totales
(JPY) | sept 2024info | Cambio interanual |
---|---|---|
Efectivo y a corto plazo | 24,36 mil M | 31,90 % |
Activos totales | 158,34 mil M | 6,87 % |
Responsabilidades totales | 69,77 mil M | -3,36 % |
Patrimonio total | 88,57 mil M | — |
Acciones en circulación | 44,08 M | — |
Precio-valor contable | 1,12 | — |
Rentabilidad económica | 4,06 % | — |
Retorno sobre capital | 4,89 % | — |
Flujo de caja
Variación neta del flujo de caja
(JPY) | sept 2024info | Cambio interanual |
---|---|---|
Ingresos netos | 1849,00 M | -25,47 % |
Efectivo de operaciones | — | — |
Efectivo de inversión | — | — |
Efectivo de financiación | — | — |
Variación neta del flujo de caja | — | — |
Flujo de caja libre | — | — |
Información sobre la empresa
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
Director ejecutivo
Fundación
22 dic 1955
Sitio web
Empleados
1.777